Pharming Group N.V. (PHAR)
- Previous Close
9.60 - Open
9.53 - Bid --
- Ask --
- Day's Range
9.53 - 9.94 - 52 Week Range
9.27 - 16.71 - Volume
1,703 - Avg. Volume
2,688 - Market Cap (intraday)
659.989M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.16 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
www.pharming.comRecent News: PHAR
Performance Overview: PHAR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHAR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHAR
Valuation Measures
Market Cap
650.19M
Enterprise Value
608.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.90
Price/Book (mrq)
3.02
Enterprise Value/Revenue
2.48
Enterprise Value/EBITDA
61.59
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.30%
Return on Assets (ttm)
-3.06%
Return on Equity (ttm)
-4.98%
Revenue (ttm)
245.32M
Net Income Avi to Common (ttm)
-10.55M
Diluted EPS (ttm)
-0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
213.42M
Total Debt/Equity (mrq)
78.41%
Levered Free Cash Flow (ttm)
8.06M